WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Nektar Therapeutics (NASDAQ: NKTR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Nektar Therapeutics is a biopharmaceutical company that focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer.

If you purchased Nektar Therapeutics (NASDAQ: NKTR) shares prior to February 26, 2025, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.  Alternatively, if you purchased Nektar securities between February 26, 2025, and December 15, 2025, you can participate in the class action.  Please contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085 to learn more.

WHY? According to a recently filed federal securities fraud class action lawsuit, Nektar Therapeutics (NASDAQ: NKTR), through certain of  its executives, violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On December 16, 2025, Nektar issued a press release "announc[ing] topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator." The press release disclosed that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate.

WHAT CAN YOU DO NOW? If you purchased Nektar Therapeutics (NASDAQ: NKTR) shares prior to February 26, 2025, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.   Alternatively, if you purchased Nektar securities between February 26, 2025, and December 15, 2025, you can participate in the class action.

#NKTR $NKTR #Nektar